Aligning Clinical Research with FDA and EMA Regulatory Strategies

Clinical study results should be interpreted and reported accurately, including neutral or unfavorable findings, limitations, uncertainty, adverse events, and protocol deviations, without selective reporting or misrepresentation.

Clinical Research

International acceptance depends on the relevant jurisdiction, product type, regulatory purpose, study design, population, GCP and quality standards, documentation, data integrity, and whether the evidence meets the receiving authority's requirements.

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

Clinical Research

International acceptance depends on the relevant jurisdiction, product type, regulatory purpose, study design, population, GCP and quality standards, documentation, data integrity, and whether the evidence meets the receiving authority's requirements.

  • Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.
  • Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.
  • Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

  1. Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.
  2. Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.
  3. International acceptance depends on the relevant jurisdiction, product type, regulatory purpose, study design, population, GCP and quality standards, documentation, data integrity, and whether the evidence meets the receiving authority's requirements.

Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

1. Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

2. Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

3. Data Management

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

4. Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

5. Clinical Research

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

Conclusion

Study reports should present methods, participant disposition, analyses, results, adverse events, protocol deviations, limitations, and conclusions accurately. Publication and communication should avoid selective reporting, unsupported causal claims, or omission of material limitations.

The Academy of Medical Sciences, Vietnam approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.

Quick Contact